甲状腺疾患治療市場の2028年までの予測- 疾患タイプ、投与経路、薬剤クラス、薬剤タイプ、流通チャネル、地域別の世界分析

Stratistics MRCによると、世界の甲状腺疾患治療市場は、2022年に27億2,685万米ドルを占め、2028年には 38億2,451万米ドルに達すると予測され、予測期間中に5.8％のCAGRで成長するとされています。

甲状腺は内分泌腺の一つで、体の代謝をコントロールするのに役立つホルモンを促進します。甲状腺が甲状腺ホルモンを過剰に分泌したり、不足したりすると、体の代謝や機能に支障をきたします。甲状腺の病気の主な原因の一つは、体内のヨウ素不足です。世界では20億人以上がヨード欠乏症の危険にさらされていると考えられており、その半数は誤診されています。また、これらの人の大半は未診断であり、その大半は低開発国に存在します。機能的または構造的な問題が甲状腺疾患の原因となることがあります。女性や高齢者はこの病気にかかりやすいと言われています。

米国保健福祉省が発表した数字によると、米国では毎年約1.2％の人が甲状腺機能低下症に罹患しているといいます。さらに、女性は男性の2～10倍甲状腺疾患にかかりやすいと言われています。

市場力学：

促進要因

促進要因：診断・治療技術の進歩

甲状腺疾患治療市場では、診断および治療技術の進歩がいくつか見られ、患者の転帰や生活の質の向上に寄与しています。診断技術の面では、超音波は、音波を使用して甲状腺の画像を作成する非侵襲的なイメージング技術です。甲状腺の結節を検出するために使用されることが多く、結節ががんであるか良性であるかを判断するのに役立ちます。また、細針吸引生検は、細い針を使って甲状腺の細胞を採取し、分析する診断法です。診断および治療技術の進歩により、甲状腺疾患治療市場は大幅に改善され、患者の転帰と生活の質の向上につながり、予測期間中に市場の成長を加速させるでしょう。

抑制要因

副作用と合併症

甲状腺疾患は、未治療のまま放置したり、治療が正しく管理されなかったりすると、いくつかの合併症につながる可能性があります。甲状腺疾患の治療法は、疾患の種類や重症度によって異なりますが、すべての治療法は副作用や合併症のリスクを伴います。甲状腺の病気には効果的な治療法がありますが、どの治療法にも副作用や合併症のリスクがあります。医療従事者と密接に連携して治療を管理し、潜在的な副作用や合併症を監視することが不可欠であり、これがフォグコンピューティング市場の成長を阻害すると予測されます。

機会

甲状腺疾患の有病率の増加

甲状腺疾患は世界中でますます蔓延し、何百万人もの人々に影響を及ぼしています。甲状腺疾患の有病率は上昇傾向にあり、いくつかの要因がこの動向に寄与しています。年齢が重要な要因であり、年齢が高くなるにつれて甲状腺疾患の発症リスクは高まると言われています。また、女性は男性よりも甲状腺疾患を発症しやすいと言われています。放射線や特定の化学物質への暴露などの環境要因は、甲状腺疾患の発症リスクを高める可能性があります。また、甲状腺疾患の家族歴があると、発症のリスクが高まります。

脅威

厳しい規制政策

甲状腺疾患治療市場は、治療の安全性と有効性を確保するため、厳格な規制方針の対象となっています。これらの政策は、米国の食品医薬品局（FDA）、欧州の欧州医薬品庁（EMA）、および世界中のその他の国の規制機関などの規制機関によって実施されます。甲状腺疾患の治療に関する規制方針には、医薬品、医療機器、その他の治療法の安全性と有効性を確立するための前臨床試験と臨床試験の要件が含まれています。これらの試験は、試験デザイン、患者募集、倫理的配慮に関する厳格なガイドラインを遵守する必要があります。厳しい規制方針は甲状腺疾患治療市場の企業にとって課題となりますが、患者さんに対する治療法の安全性と有効性を確保するためには不可欠なものとなっています。

COVID-19の影響：

COVIDの期間中、大半の産業で悪影響が見られました。これは、世界各国の政府機関によって課された様々な予防的ロックダウンやその他の制限が、それぞれの生産およびサプライチェーン業務に多大な混乱を引き起こしたことに起因しています。甲状腺疾患の治療薬の世界市場も同様です。さらに、大多数の人々の一般的な経済状況がこのアウトブレイクによって大きな影響を受けたため、人々は自分の予算から必要でない支出を削減する意欲を高め、消費者需要は今や減少しています。

予測期間中、甲状腺機能亢進症分野が最も大きくなると予想される

甲状腺によるサイロキシンの過剰生産により、甲状腺機能亢進症が発生します。甲状腺がんや甲状腺機能亢進症の有病率が世界的に上昇していることなどから、この分野は予測期間中に大きく発展すると予想されています。2022年7月に発表されたStatPearlsの記事によると、潜在性甲状腺機能亢進症は男性よりも65歳以上の女性に多く発症し、一方、顕性甲状腺機能亢進症の割合は女性1000人あたり0.4、男性1000人あたり0.1で、年齢によって異なります。甲状腺機能亢進症の有病率が高いことから、この疾患に対する最先端の治療法の創出が期待され、予測期間中の市場拡大の原動力となることが予想されます。

予測期間中、レボサイロキシンのCAGRが最も高くなると予想されます。

予測期間中、甲状腺機能低下症の治療薬としては、レボチロキシンが最も高いCAGRを維持すると予想されます。甲状腺機能低下症および甲状腺機能亢進症セグメントは、甲状腺の問題の治療に用いられる薬剤の市場の大半を占めています。レボサイロキシンやリオサイロニンは、甲状腺機能低下症の治療に用いられる薬剤の一例です。甲状腺疾患治療市場は、主に甲状腺疾患の世界の有病率の増加、新興国・先進国の双方におけるレボチロキシンを含む医薬品の需要の高まり、甲状腺医薬品のトップメーカーによる最先端の治療薬の創出への取り組みの継続により、穏やかな速度で成長しています。

最もシェアの高い地域：

予想される期間中、北米が最大の収益シェアを占めています。この地域は、効率的なヘルスケア施設の存在、人々の知識レベルの高さ、利用可能な治療法の幅広さなどが、高い収益シェアの理由の1つです。同地域では、特にジェネリック医薬品の製造や医療従事者の意識向上のために、製薬会社と政府機関の戦略的提携が進んでいます。このため、北米の市場はかなり収益性が高いです。例えば、Genzyme社は、Veracyte社との提携により、甲状腺の問題を管理するためのオーダーメイドの治療法を提供する予定です。

CAGRが最も高い地域：

予測期間中、アジア太平洋は最も速い成長率を示すと予測されています。この地域では、甲状腺疾患の有病率が高く、ヘルスケア支出が増加しているため、この地域のメーカーは、より高い効率を持つ低価格製品の開発に注力しています。また、原材料や人件費の安さに惹かれて、世界のプレーヤーがこの地域の現地企業に投資しています。さらに、甲状腺関連疾患や甲状腺がんに関する認識を高めるため、世界各地で「甲状腺意識向上月間」が開催されました。このような取り組みにより、早期発見・早期治療が促進され、予測期間中の市場成長を促進すると期待されています。

主な発展：

2022年11月：米国の子会社であるZydus Lifesciences社が、甲状腺ホルモン欠乏症の治療に用いられるレボチロキシンナトリウム注射液の販売承認を米国連邦医薬品庁（USFDA）から取得しました。

2022年5月、米国食品医薬品局（FDA）は、イーライリリー・アンド・カンパニーの新しい週1回投与のGIP（グルコース依存性インスリントロピックポリペプチド）およびGLP-1（グルカゴン様ペプチド-1）受容体作動薬であり、成人の2型糖尿病の血糖コントロールを改善するための食事と運動への補助として適応する「マウンジャロ（tirzepatide）注射剤」を承認しました。

2021年9月、Exelixis Inc.は、CABOMETYX（カボザンチニブ）について、血管内皮増殖因子受容体（VEGFR）を標的とした先行治療後に進行した局所進行または転移性分化型甲状腺がん（DTC）で、放射性ヨード不応症または不適格の成人および小児患者に対する治療のためのUSFDA承認を取得。

本レポートの内容

• 地域レベルおよび国レベルセグメントにおける市場シェア評価
• 新規参入企業への戦略的提言
• 2020年、2021年、2022年、2025年、2028年の市場データを網羅
• 市場動向（促進要因、抑制要因、機会、脅威、課題、投資機会、推奨事項）
• 市場推定に基づく、主要ビジネスセグメントにおける戦略的提言
• 主要な共通トレンドをマッピングした競合情勢。
• 詳細な戦略、財務、最近の開発状況を含む企業プロファイル
• 最新の技術的進歩をマッピングしたサプライチェーン動向

無料のカスタマイズ提供：

本レポートをご購入いただいたお客様には、以下の無料カスタマイズオプションのいずれかを提供させていただきます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的なプロファイリング（最大3社まで）
  • 主要プレイヤーのSWOT分析（3社まで）
• 地域別セグメンテーション
  • お客様のご希望に応じて、主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる。）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地域的プレゼンス、戦略的提携に基づく主要プレイヤーのベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 仮定

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の甲状腺疾患治療市場：疾患タイプ別

• 甲状腺機能低下症
• 甲状腺機能亢進症
• その他

第6章 世界の甲状腺疾患治療市場：投与経路別

• 経口
• 非経口
• 経静脈
• その他

第7章 世界の甲状腺疾患治療市場：薬剤クラス別

• チオアミド
• イオン性阻害剤
• ホルモン放出阻害剤
• その他

第8章 世界の甲状腺疾患治療市場：薬剤タイプ別

• レボチロキシン
• リオチロニン
• プロピルチオウラシル
• イミダゾール系化合物
• その他

第9章 世界の甲状腺疾患治療市場：流通チャネル別

• 卸売流通
• 小売店
• オンライン薬局
• 通信販売薬局
• その他の流通チャネル

第10章 世界の甲状腺疾患治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第11章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第12章 会社概要

• Abbott Laboratories
• AbbVie Inc.
• ALLERGAN
• Alvogen ehf
• Amgen Inc.
• Aspen
• Elexis Inc.
• GlaxoSmithKline Plc
• GSK Plc
• IBSA Pharma（IBSA Group）
• Lannett Co. Inc.
• Merck KGaA
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• RLC Labs Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

List of Tables

• Table 1 Global Thyroid Gland Disorders Treatment Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 3 Global Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 4 Global Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 5 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 6 Global Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 7 Global Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 8 Global Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 9 Global Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 10 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 11 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 12 Global Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 13 Global Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 14 Global Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 15 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 16 Global Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 17 Global Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 18 Global Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 19 Global Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 20 Global Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 21 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 22 Global Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 23 Global Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 24 Global Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 25 Global Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 26 Global Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 27 Global Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
• Table 28 North America Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 29 North America Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 30 North America Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 31 North America Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 32 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 33 North America Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 34 North America Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 35 North America Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 36 North America Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 37 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 38 North America Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 39 North America Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 40 North America Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 41 North America Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 42 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 43 North America Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 44 North America Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 45 North America Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 46 North America Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 47 North America Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 48 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 49 North America Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 50 North America Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 51 North America Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 52 North America Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 53 North America Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 54 North America Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
• Table 55 Europe Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 56 Europe Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 57 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 58 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 59 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 60 Europe Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 61 Europe Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 62 Europe Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 63 Europe Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 64 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 65 Europe Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 66 Europe Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 67 Europe Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 68 Europe Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 69 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 70 Europe Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 71 Europe Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 72 Europe Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 73 Europe Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 74 Europe Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 75 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 76 Europe Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 77 Europe Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 78 Europe Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 79 Europe Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 80 Europe Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 81 Europe Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
• Table 82 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 83 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 84 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 85 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 86 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 87 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 88 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 89 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 90 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 91 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 92 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 93 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 94 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 95 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 96 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 97 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 98 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 99 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 100 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 101 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 102 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 103 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 104 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 105 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 106 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 107 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 108 Asia Pacific Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
• Table 109 South America Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 110 South America Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 111 South America Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 112 South America Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 113 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 114 South America Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 115 South America Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 116 South America Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 117 South America Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 118 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 119 South America Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 120 South America Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 121 South America Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 122 South America Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 123 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 124 South America Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 125 South America Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 126 South America Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 127 South America Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 128 South America Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 129 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 130 South America Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 131 South America Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 132 South America Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 133 South America Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 134 South America Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 135 South America Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
• Table 136 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Country (2020-2028) ($MN)
• Table 137 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Type of Disorder (2020-2028) ($MN)
• Table 138 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hypothyroidism (2020-2028) ($MN)
• Table 139 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hyperthyroidism (2020-2028) ($MN)
• Table 140 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Types of Disorders (2020-2028) ($MN)
• Table 141 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Route of Administration (2020-2028) ($MN)
• Table 142 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Oral (2020-2028) ($MN)
• Table 143 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Parenteral (2020-2028) ($MN)
• Table 144 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Intravenous Route (2020-2028) ($MN)
• Table 145 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Routes of Administrations (2020-2028) ($MN)
• Table 146 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Drug Class (2020-2028) ($MN)
• Table 147 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Thioamides (2020-2028) ($MN)
• Table 148 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Ionic Inhibitors (2020-2028) ($MN)
• Table 149 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Hormone-release Inhibitors (2020-2028) ($MN)
• Table 150 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Classes (2020-2028) ($MN)
• Table 151 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Drug Type (2020-2028) ($MN)
• Table 152 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Levothyroxine (2020-2028) ($MN)
• Table 153 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Liothyronine (2020-2028) ($MN)
• Table 154 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Propylthiouracil (2020-2028) ($MN)
• Table 155 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Imidazole-Based Compounds (2020-2028) ($MN)
• Table 156 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Drug Types (2020-2028) ($MN)
• Table 157 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Distribution Channel (2020-2028) ($MN)
• Table 158 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Wholesale Distribution (2020-2028) ($MN)
• Table 159 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Retail Stores (2020-2028) ($MN)
• Table 160 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Online Pharmacy (2020-2028) ($MN)
• Table 161 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Mail-Order Pharmacy (2020-2028) ($MN)
• Table 162 Middle East & Africa Thyroid Gland Disorders Treatment Market Outlook, By Other Distribution Channels (2020-2028) ($MN)

According to Stratistics MRC, the Global Thyroid Gland Disorders Treatment Market is accounted for $2726.85 million in 2022 and is expected to reach $3824.51 million by 2028 growing at a CAGR of 5.8% during the forecast period. A thyroid gland is an endocrine gland that promotes hormones that assist in controlling the body's metabolism. The body's metabolism and functionality are hampered when the thyroid gland produces too many or insufficient thyroid hormones. One of the main causes of thyroid diseases is a shortage of iodine in the body. More than 2 billion people are thought to be at risk of iodine deficiency globally, and half of those individuals are misdiagnosed. The majority of these individuals are undiagnosed, with the majority being in underdeveloped nations. Functional or structural problems can cause thyroid diseases. Women and the elderly are more likely to have this illness.

According to numbers published by the U.S. Department of Health and Human Services, around 1.2% people in the U.S. suffer from hypothyroidism each year. Moreover, women 2-10 times more susceptible than men to develop thyroid conditions.

Market Dynamics:

Driver:

Advancements in diagnostic and treatment technologies

There have been several advancements in diagnostic and treatment technologies in the Thyroid Gland Disorders Treatment Market, leading to improved patient outcomes and quality of life. In terms of diagnostic technologies, ultrasound is a non-invasive imaging technique that uses sound waves to create images of the thyroid gland. It is often used to detect thyroid nodules and can help determine whether a nodule is cancerous or benign. Fine-needle aspiration biopsy is another diagnostic technique that involves using a thin needle to extract cells from the thyroid gland for analysis. Advancements in diagnostic and treatment technologies have significantly improved the Thyroid Gland Disorders Treatment Market, leading to better patient outcomes and quality of life, which will accelerate market growth over the course of the forecast period.

Restraint:

Side effects and complications

Thyroid gland disorders can lead to several complications if left untreated or if treatment is not managed correctly. Treatment options for thyroid gland disorders vary depending on the specific type and severity of the disorder, but all treatments carry the risk of side effects and complications. While there are effective treatments available for thyroid gland disorders, all treatments carry the risk of side effects and complications. It is essential to work closely with a healthcare provider to manage treatment and monitor for any potential side effects or complications, which are projected to impede the fog computing market's growth.

Opportunity:

Growing prevalence of thyroid gland disorders

Thyroid gland disorders are increasingly prevalent worldwide, affecting millions of people. The prevalence of thyroid gland disorders is on the rise, and several factors contribute to this trend. Age is a significant factor, with the risk of developing a thyroid disorder increasing as one grows older. Women are also more likely to develop thyroid gland disorders than men. Environmental factors, such as exposure to radiation or certain chemicals, can increase the risk of developing a thyroid disorder. A family history of thyroid gland disorders also increases the risk of developing the condition.

Threat:

Stringent regulatory policies

The Thyroid Gland Disorders Treatment Market is subject to stringent regulatory policies to ensure the safety and efficacy of treatments. These policies are put in place by regulatory bodies such as the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in Europe, and other national regulatory agencies worldwide. Regulatory policies for thyroid gland disorders treatments include requirements for preclinical and clinical trials to establish the safety and efficacy of drugs, medical devices, and other treatments. These trials must adhere to strict guidelines for study design, patient recruitment, and ethical considerations. While stringent regulatory policies can create challenges for companies in the Thyroid Gland Disorders Treatment Market, they are essential to ensure the safety and efficacy of treatments for patients.

COVID-19 Impact:

Over the time frame of COVID, the majority of industries saw adverse effects. This can be attributed to the enormous disruptions that various precautionary lockdowns and other limitations that were imposed by governing agencies around the world caused in their respective production and supply-chain operations. The same is true for the global market for treatments for thyroid gland disorders. Additionally, consumer demand has now decreased as people have become more motivated to cut non-essential spending from their own budgets, as the general economic situation of the majority of people has been badly impacted by this outbreak.

The Hyperthyroidism segment is expected to be the largest during the forecast period

The overproduction of thyroxin by the thyroid gland results in hyperthyroidism. The category is anticipated to develop significantly over the projected period due to factors like the rising prevalence of thyroid cancer and hyperthyroidism around the world. Subclinical hyperthyroidism affects more women over 65 than males, according to a StatPearls article published in July 2022, whereas rates of overt hyperthyroidism are 0.4 per 1000 women and 0.1 per 1000 men and vary with age. The high prevalence of hyperthyroidism is anticipated to open up prospects for the creation of cutting-edge therapies for the condition, which is anticipated to fuel market expansion over the course of the projected period.

The levothyroxine segment is expected to have the highest CAGR during the forecast period

Throughout the projected period, levothyroxine will continue to see the highest CAGR for the treatment of hypothyroidism. The hypothyroidism and hyperthyroidism segments make up the majority of the market for drugs used to treat thyroid gland problems. Levothyroxine and liothyronine are examples of medications used to treat hypothyroidism. The market for the treatment of thyroid disorders is growing at a moderate rate, primarily as a result of the increased global prevalence of thyroid disorders, rising demand for levothyroxine-containing medications in both developing and developed regions, and ongoing efforts by top thyroid drug producers to create cutting-edge therapeutics.

Region with largest share:

Over the course of the anticipated period, North America accounted for the biggest revenue share. One reason for its high revenue share is the existence of efficient healthcare facilities, higher knowledge levels among people, and a wide range of available treatment alternatives. In the region, strategic alliances between pharmaceutical firms and governmental bodies are growing, especially to create generic medications and raise awareness among healthcare professionals. Because of this, the market in North America is quite profitable. For instance, Genzyme will offer tailored treatments for the management of thyroid gland problems in collaboration with Veracyte Inc.

Region with highest CAGR:

During the forecast period, Asia-Pacific is anticipated to have the fastest growth rate. Due to the increasing prevalence of thyroid disorders in the region and rising healthcare expenditure, as manufacturers in this region are focusing on the development of low-cost products with higher efficiency. In addition, global players are investing in local companies in the region, attracted by the lower cost of raw material and labor. Additionally, Thyroid Awareness Month was celebrated worldwide to raise awareness regarding thyroid-related diseases and thyroid cancer. Such initiatives are expected to boost early detection and treatment, which is expected to propel the market growth during the forecast period.

Key players in the market:

Some of the key players in Thyroid Gland Disorders Treatment Market include Abbott Laboratories, AbbVie Inc., ALLERGAN, Alvogen ehf, Amgen Inc., Aspen, Elexis Inc., GlaxoSmithKline Plc, GSK Plc, IBSA Pharma (IBSA Group), Lannett Co. Inc., Merck KGaA, Mylan N.V., Novartis AG, Pfizer Inc., RLC Labs Inc., Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd. and Viatris Inc.

Key Developments:

In Nov 2022: Zydus Lifesciences, a US-based subsidiary, received approval from the USFDA to market Levothyroxine Sodium injection, used to treat thyroid hormone deficiency.

In May 2022: The United States Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection, Eli Lilly and Company's new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In September 2021, Exelixis Inc. received USFDA approval for CABOMETYX (cabozantinib) for the treatment of adult and pediatric patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible.

Type of Disorders Covered:

• Hypothyroidism
• Hyperthyroidism
• Other Types of Disorders

Route of Administrations Covered:

• Oral
• Parenteral
• Intravenous Route
• Other Routes of Administrations

Drug Classes Covered:

• Thioamides
• Ionic Inhibitors
• Hormone-release Inhibitors
• Other Drug Classes

Drug Types Covered:

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-Based Compounds
• Other Drug Types

Distribution Channels Covered:

• Wholesale Distribution
• Retail Stores
• Online Pharmacy
• Mail-Order Pharmacy
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Thyroid Gland Disorders Treatment Market, By Type of Disorder

• 5.1 Introduction
• 5.2 Hypothyroidism
• 5.3 Hyperthyroidism
• 5.4 Other Types of Disorders

6 Global Thyroid Gland Disorders Treatment Market, By Route of Administration

• 6.1 Introduction
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Intravenous Route
• 6.5 Other Routes of Administrations

7 Global Thyroid Gland Disorders Treatment Market, By Drug Class

• 7.1 Introduction
• 7.2 Thioamides
• 7.3 Ionic Inhibitors
• 7.4 Hormone-release Inhibitors
• 7.5 Other Drug Classes

8 Global Thyroid Gland Disorders Treatment Market, By Drug Type

• 8.1 Introduction
• 8.2 Levothyroxine
• 8.3 Liothyronine
• 8.4 Propylthiouracil
• 8.5 Imidazole-Based Compounds
• 8.6 Other Drug Types

9 Global Thyroid Gland Disorders Treatment Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Wholesale Distribution
• 9.3 Retail Stores
• 9.4 Online Pharmacy
• 9.5 Mail-Order Pharmacy
• 9.6 Other Distribution Channels

10 Global Thyroid Gland Disorders Treatment Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Abbott Laboratories
• 12.2 AbbVie Inc.
• 12.3 ALLERGAN
• 12.4 Alvogen ehf
• 12.5 Amgen Inc.
• 12.6 Aspen
• 12.7 Elexis Inc.
• 12.8 GlaxoSmithKline Plc
• 12.9 GSK Plc
• 12.10 IBSA Pharma (IBSA Group)
• 12.11 Lannett Co. Inc.
• 12.12 Merck KGaA
• 12.13 Mylan N.V.
• 12.14 Novartis AG
• 12.15 Pfizer Inc.
• 12.16 RLC Labs Inc.
• 12.17 Sanofi
• 12.18 Takeda Pharmaceutical Company Limited
• 12.19 Teva Pharmaceutical Industries Ltd.
• 12.20 Viatris Inc.